DOJ False Claims Act Investigations: Whistleblower Role

The False Claims Act (31 U.S.C. §§ 3729–3733) is the federal government's primary civil enforcement tool against fraud involving government funds, and the Department of Justice plays a central role in deciding how qui tam complaints filed by private whistleblowers are handled. This page covers the structure of DOJ's investigative process, the specific functions whistleblowers serve within that framework, the fraud categories most commonly pursued, and the boundaries that determine when DOJ intervenes versus declines. Understanding this process is foundational to any analysis of False Claims Act qui tam litigation and its outcomes.

Definition and scope

The False Claims Act imposes civil liability on any person or entity that knowingly submits a false or fraudulent claim for payment to the federal government (31 U.S.C. § 3729(a)). Penalties per false claim are set by statute and adjusted periodically for inflation; as of the Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015, the per-claim civil penalty range runs from $13,946 to $27,894 (DOJ Civil Division, 2023 adjustment).

The qui tam mechanism, codified at 31 U.S.C. § 3730(b), authorizes a private individual — referred to as a "relator" — to file a lawsuit on behalf of the United States. The case is filed under seal and served on the DOJ, which then has 60 days (extendable by court order) to investigate and decide whether to intervene. DOJ intervention means the government formally joins the litigation and assumes primary control of the case.

The scope of covered conduct is broad. Any claim submitted to a federal program — Medicare, Medicaid, defense procurement, research grants, housing assistance, or customs duties — falls within the Act's reach. The DOJ Civil Division's Fraud Section and its network of U.S. Attorney's Offices across 94 judicial districts jointly administer FCA enforcement. Relators retain an interest in the litigation regardless of whether DOJ intervenes, though the procedural posture differs substantially between the two tracks, a distinction addressed in the whistleblower complaint filing process.

How it works

DOJ's investigative process following a qui tam filing follows a structured sequence:

1. Seal and assignment. Upon filing, the complaint is placed under seal by the district court. DOJ and the relevant U.S. Attorney's Office receive a copy along with a written disclosure of substantially all material evidence the relator possesses (31 U.S.C. § 3730(b)(2)).

2. Preliminary review. DOJ attorneys conduct an initial assessment of jurisdictional sufficiency, the plausibility of the alleged scheme, and whether overlapping investigations already exist within the Civil or Criminal Divisions.

3. Active investigation. If the complaint clears preliminary review, investigators — typically FBI agents, HHS-OIG agents, or agency inspectors general — conduct subpoenas, document requests, witness interviews, and in some cases grand jury proceedings running parallel to the civil inquiry.

4. Intervention decision. DOJ must either intervene, decline, or seek additional seal extensions. When DOJ intervenes, the case proceeds as a government-led civil action. When DOJ declines, the relator may continue prosecuting the case independently under 31 U.S.C. § 3730(c)(3), though success rates in declined cases are substantially lower.

5. Resolution. Cases resolve through settlement, judgment, or dismissal. DOJ settlements require court approval, and the relator retains the right to object to settlement terms that affect their share of the recovery.

The relator's award is set by statute: between 15% and 25% of the recovery when DOJ intervenes, and between 25% and 30% when the relator proceeds without DOJ participation (31 U.S.C. § 3730(d)). Detailed award calculation methodology is covered separately in whistleblower award calculations.

Common scenarios

DOJ FCA investigations cluster around identifiable fraud categories. The categories below represent the highest-volume enforcement areas tracked by DOJ's annual FCA statistics:

Healthcare fraud. Billing Medicare or Medicaid for services not rendered, upcoding procedure codes, kickback arrangements prohibited under the Anti-Kickback Statute (42 U.S.C. § 1320a-7b), and off-label drug promotion constitute the dominant FCA category. DOJ recovered more than $1.8 billion in healthcare-related FCA settlements and judgments in fiscal year 2022 (DOJ FCA Statistics, FY2022). The healthcare fraud whistleblower framework provides additional program-specific context.

Defense and government contracting. Contractors submitting inflated invoices, misrepresenting product specifications, or billing for work not performed under defense procurement contracts face FCA exposure. The Defense Contract Audit Agency (DCAA) frequently serves as a referral source for DOJ investigations. Government contractor whistleblower rights govern protections specific to this sector.

Research grant fraud. Universities and research institutions that falsify data, misuse grant funds, or misrepresent compliance with federal requirements face liability under grants administered by NIH, NSF, and other federal agencies.

Financial fraud. Mortgage fraud schemes targeting HUD-insured loans, false certifications to the Small Business Administration, and customs fraud are recurring FCA targets. See financial fraud whistleblower for program-specific coverage.

Decision boundaries

Not every qui tam filing results in DOJ intervention or ultimate success. The factors that drive DOJ's intervention decision function as hard structural boundaries:

Originality requirement. The public disclosure bar (31 U.S.C. § 3730(e)(4)) prohibits qui tam suits based on fraud already publicly disclosed through specified channels — government hearings, news media, or government reports — unless the relator qualifies as an "original source" with direct and independent knowledge. This bar has been litigated extensively and functions as a threshold jurisdictional question.

Specificity of evidence. DOJ weighs the relator's disclosure statement against the investigative resources required. Complaints based on pattern inference without documentary support receive lower priority than those accompanied by billing records, emails, or internal compliance reports.

Intervention vs. declination contrast. When DOJ intervenes, settlement rates exceed 90% of resolved cases (DOJ Civil Division data). When DOJ declines, relators face the full litigation burden against institutional defendants, and courts may dismiss under § 3730(c)(3) if the government's interests are threatened by continued prosecution.

Retaliation protections. Employees who face adverse employment action for engaging in FCA-protected activity — including investigation, filing, or testimony — hold a separate cause of action under 31 U.S.C. § 3730(h). This protection operates independently of the underlying qui tam claim. The scope of those protections is addressed in whistleblower retaliation protections and retaliation remedies and damages.

Statute of limitations. FCA claims must be filed within 6 years of the violation or within 3 years of when the government knew or should have known of the violation — but no more than 10 years from the date of the violation (31 U.S.C. § 3731(b)). Timing analysis is covered in statutes of limitations for whistleblower claims.

References

• False Claims Act, 31 U.S.C. §§ 3729–3733 — House Office of Law Revision Counsel
• DOJ Civil Division — False Claims Act Overview and Statistics
• HHS Office of Inspector General — Fraud and Abuse
• Defense Contract Audit Agency (DCAA)
• Federal Civil Penalties Inflation Adjustment Act Improvements Act of 2015 — eCFR
• Anti-Kickback Statute, 42 U.S.C. § 1320a-7b — House Office of Law Revision Counsel